Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KALA BIO, Inc.KALA · Entity 7964 | Director | June 15, 2025 | June 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KALA BIO, Inc.
Report date June 15, 2025 · Filed June 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,242 |
Reported balance
After 2025-06-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-15 · Grant · Acquired 2,450 · Balance 10,242 F1: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026. F2: Includes 5,134 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.30 · Expires 2035-06-14 | Direct | 5,450 |
Reported balance
After 2025-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-15 · Grant · Acquired 5,450 · Balance 5,450 F3: This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.
F2: Includes 5,134 unvested RSUs.
F3: This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2025 Filed Jun 18, 2025 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 5,450 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001415889-25-017614 · form4-06172025_080609.xml · derivative · entry 2 Farid Marjan · CIK 0001952098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,450 Underlying: Common Stock · 5,450 shares Expires 2035-06-14 F3 · derivative.exercise_date: This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026. Read SEC document |
| June 15, 2025 Filed Jun 18, 2025 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantCommon Stock | 2,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017614 · form4-06172025_080609.xml · nonDerivative · entry 1 Farid Marjan · CIK 0001952098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,242 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026. F2 · balance_after: Includes 5,134 unvested RSUs. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 3,150 | $0.00 Strike: $6.18 | $0.00 |
DisclosureSEC source: 0001415889-24-016573 · form4-06122024_080612.xml · derivative · entry 2 Farid Marjan · CIK 0001952098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,150 Underlying: Common Stock · 3,150 shares Expires 2034-06-10 F3 · derivative.exercise_date: This option was granted on June 11, 2024 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantCommon Stock | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016573 · form4-06122024_080612.xml · nonDerivative · entry 1 Farid Marjan · CIK 0001952098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,792 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024. F2 · balance_after: Includes 6,692 unvested RSUs. Read SEC document |
| June 22, 2023 Filed Jun 24, 2023 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001415889-23-010292 · form4-06232023_080626.xml · derivative · entry 4 Farid Marjan · CIK 0001952098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2033-06-21 F6 · derivative.exercise_date: This option was granted on June 22, 2023 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023. Read SEC document |
| June 22, 2023 Filed Jun 24, 2023 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 4,922 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001415889-23-010292 · form4-06232023_080626.xml · derivative · entry 3 Farid Marjan · CIK 0001952098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,922 Underlying: Common Stock · 4,922 shares Expires 2033-06-21 F5 · derivative.exercise_date: This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter. Read SEC document |
| June 22, 2023 Filed Jun 24, 2023 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantCommon Stock | 1,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-010292 · form4-06232023_080626.xml · nonDerivative · entry 2 Farid Marjan · CIK 0001952098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,392 F3 · security: Grant of RSUs under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023. F4 · balance_after: Includes 6,392 unvested RSUs. Read SEC document |
| June 22, 2023 Filed Jun 24, 2023 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantCommon Stock | 3,692 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-010292 · form4-06232023_080626.xml · nonDerivative · entry 1 Farid Marjan · CIK 0001952098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,292 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026. F2 · balance_after: Includes 5,292 unvested RSUs. Read SEC document |
| May 31, 2023 Filed Jun 3, 2023 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | Disposition to issuerStock Option (right to buy) · Derivative | 1,600 | Not disclosed Strike: $6.35 | Not disclosed |
DisclosureSEC source: 0001415889-23-009143 · form4-06022023_080643.xml · derivative · entry 2 Farid Marjan · CIK 0001952098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,600 shares Expires 2032-10-30 F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange for the unvested options, the reporting person received a grant of 1,600 RSUs that vest over three years, with 86% of such RSUs vesting on May 31, 2025 and 14% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The cancelled option was granted on October 31, 2022 and provided for vesting with respect to 1/3rd of the shares underlying the option on October 31, 2023 and as to an additional 1/36th of the shares underlying the option at the end of each successive one-month period thereafter until October 31, 2025. Read SEC document |
| May 31, 2023 Filed Jun 3, 2023 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantCommon Stock | 1,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-009143 · form4-06022023_080643.xml · nonDerivative · entry 1 Farid Marjan · CIK 0001952098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,600 F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange for the unvested options, the reporting person received a grant of 1,600 RSUs that vest over three years, with 86% of such RSUs vesting on May 31, 2025 and 14% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F2 · balance_after: Includes 1,600 unvested RSUs. Read SEC document |
| October 31, 2022 Filed Nov 1, 2022 20:12 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 1,600 | $0.00 Strike: $6.35 | $0.00 |
DisclosureSEC source: 0001415889-22-010936 · form4-11012022_011127.xml · derivative · entry 1 Farid Marjan · CIK 0001952098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 Underlying: Common Stock · 1,600 shares Expires 2032-10-30 F1 · derivative.exercise_date: This option was granted on October 31, 2022 and vests with respect to 1/3rd of the shares underlying the option on October 31, 2023 and as to an additional 1/36th of the shares underlying the option at the end of each successive one-month period thereafter until October 31, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.